Xilio Therapeutics (XLO) Cash Flow: Operating & Free Cash Flow

Xilio Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Xilio Therapeutics, Inc. (XLO) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Operating Activities
Net Income	-35.04	-58.24	-76.40	-88.22	-75.80	-55.22	-17.31
Depreciation & Amortization	1.54	1.64	1.90	1.85	1.50	1.07	0.24
Deferred Income Tax	0.00	0.00	0.00	0.00	0.22	0.00	-1.74
Stock Based Compensation	6.94	6.43	7.38	8.42	4.96	1.30	0.11
Change in Working Capital	25.13	31.78	-1.66	2.00	-11.80	16.60	0.80
Change in Accounts Receivable	-5.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Accounts Payable	0.15	1.53	-2.06	0.49	-2.82	2.93	0.97
Change in Other Working Capital	3.08	-0.98	0.41	1.52	0.17	13.68	-0.17
Other Operating Activities	-3.56	0.00	0.16	0.22	0.17	0.17	0.06
Net Cash from Operating Activities	-4.99	-18.38	-68.62	-75.72	-80.75	-36.09	-17.84
Investing Activities
Capital Expenditures	-0.52	-0.04	-0.49	-1.87	-1.10	-2.19	-0.72
Net Cash from Investing Activities	-0.52	-0.04	-0.49	-1.87	-1.10	-2.19	-0.72
Financing Activities
Debt Repayment	0.00	-3.33	-6.75	-0.09	-1.09	-0.10	9.95
Common Stock Issued	87.78	32.58	0.20	0.02	116.36	0.00	0.00
Other Financing Activities	0.00	-0.05	0.00	0.00	-0.75	10.13	40.12
Net Cash from Financing Activities	87.78	29.20	-6.55	-0.07	260.67	10.03	60.02
Summary
Effect of Forex Changes on Cash	0.00	0.00	-0.03	-0.01	0.00	0.00	0.00
Net Change in Cash	82.27	10.78	-75.68	-77.67	178.82	-28.25	41.46
Cash at Beginning of Period	57.07	46.29	120.39	198.05	20.79	49.04	7.58
Cash at End of Period	139.34	57.07	44.70	120.39	199.61	20.79	49.04
Free Cash Flow	-5.51	-18.41	-69.11	-77.59	-81.85	-38.28	-18.56
Supplemental Disclosures
Interest Paid	-	0.06	0.57	0.56	0.49	0.54	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xilio Therapeutics Cash Flow

What is Xilio Therapeutics's free cash flow?

Xilio Therapeutics had negative free cash flow of $5.51M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$4.99M minus $518.00K of capital expenditures.

How much does Xilio Therapeutics spend on capital expenditures?

Xilio Therapeutics spent $518.00K on capital expenditures in fiscal 2025, compared with $36.00K a year earlier.

Does Xilio Therapeutics pay dividends or buy back shares?

Xilio Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition